| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Brain Tumor Research Centre [D. R. K., D. L. S., C. T., I. M., G. M.] and Department of Neurology and Neurosurgery [M-C. G., R. L., J. A., A. O., G. J. S.], Montreal Neurological Institute, Montreal Canada H3A 2B4, and BioChem Pharma, Inc., Laval, Quebec, H7V 4A7 Canada [C. T.]
Tumors of glial origin such as glioblastoma multiforme (GBM) comprise the majority of human brain tumors. Patients with GBM have a very poor survival rate, with an average life expectancy of <1 year. We asked whether we could identify a survival pathway in high-grade glioma and oligodendroglioma cells that when suppressed, would induce apoptosis of these tumor cells but not of normal human adult astrocytes. To identify these pathways, we selectively suppressed the activity of a number of proteins (Ras, Rac1, Akt1, RhoA, c-jun, and MEK1/2) hypothesized to play roles in cell survival. We found that suppression of Rac1, a small GTP-binding protein, inhibited survival and produced apoptosis in three human glioma cell lines (U87, U343, and U373). Serum induced the activity of Rac1 and the activity or phosphorylation state of p21-activated kinase 1 and c-Jun NH2-terminal kinase (JNK), two intracellular targets of Rac1. Suppression of Rac1 also induced apoptosis in 19 of 21 short-term cultures of human primary cells from grades II and III oligodendroglioma and grade IV glioblastoma that varied in p53, epidermal growth factor receptor, epidermal growth factor receptor vIII, MDM2, and p16/p19 mutational or amplification status. In contrast, inhibition of Rac1 activity did not induce apoptosis of normal primary human adult astrocytes. In both established glioma cell lines and primary glioma cells, apoptosis induced by the inhibition of Rac was partially rescued by activated mitogen-activated protein kinase kinase 1, an activator of JNK, suggesting that JNK functions downstream of Rac1 in glioma cells. These results indicate that Rac1 regulates a major survival pathway in most glioma cells, and that suppression of Rac1 activity stimulates the death of virtually all glioma cells, regardless of their mutational status. Agents that suppress Rac1 activity may therefore be useful therapeutic treatments for malignant gliomas.
This article has been cited by other articles:
|
|
 |
|
  H. Aoki, T. Yokoyama, K. Fujiwara, A. M. Tari, R. Sawaya, D. Suki, K. R. Hess, K. D. Aldape, S. Kondo, R. Kumar, et al. Phosphorylated Pak1 Level in the Cytoplasm Correlates with Shorter Survival Time in Patients with Glioblastoma Clin. Cancer Res., November 15, 2007; 13(22): 6603 - 6609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jin, R. M. Ray, and L. R. Johnson Rac1 mediates intestinal epithelial cell apoptosis via JNK Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1137 - G1147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Tran, W. S. McDonough, B. A. Savitch, S. P. Fortin, J. A. Winkles, M. Symons, M. Nakada, H. E. Cunliffe, G. Hostetter, D. B. Hoelzinger, et al. Increased Fibroblast Growth Factor-Inducible 14 Expression Levels Promote Glioma Cell Invasion via Rac1 and Nuclear Factor-{kappa}B and Correlate with Poor Patient Outcome Cancer Res., October 1, 2006; 66(19): 9535 - 9542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Wang, I. Shin, F. Y. Wu, D. B. Friedman, and C. L. Arteaga HER2/Neu (ErbB2) Signaling to Rac1-Pak1 Is Temporally and Spatially Modulated by Transforming Growth Factor {beta} Cancer Res., October 1, 2006; 66(19): 9591 - 9600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Foltz, G.-Y. Ryu, J.-G. Yoon, T. Nelson, J. Fahey, A. Frakes, H. Lee, L. Field, K. Zander, Z. Sibenaller, et al. Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma. Cancer Res., July 1, 2006; 66(13): 6665 - 6674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cui, M. Holgado-Madruga, W. Su, H. Tsuiki, P. Wedegaertner, and A. J. Wong Identification of a Specific Domain Responsible for JNK2{alpha}2 Autophosphorylation J. Biol. Chem., March 18, 2005; 280(11): 9913 - 9920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Angers-Loustau, R. Hering, T. E. Werbowetski, D. R. Kaplan, and R. F. Del Maestro Src Regulates Actin Dynamics and Invasion of Malignant Glial Cells in Three Dimensions Mol. Cancer Res., November 1, 2004; 2(11): 595 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Liu, F. Bi, Y. Pan, L. Sun, Y. Xue, Y. Shi, X. Yao, Y. Zheng, and D. Fan Reversal of the Malignant Phenotype of Gastric Cancer Cells by Inhibition of RhoA Expression and Activity Clin. Cancer Res., September 15, 2004; 10(18): 6239 - 6247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwadate, T. Sakaida, T. Hiwasa, Y. Nagai, H. Ishikura, M. Takiguchi, and A. Yamaura Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis Cancer Res., April 1, 2004; 64(7): 2496 - 2501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Joy, C. E. Beaudry, N. L. Tran, F. A. Ponce, D. R. Holz, T. Demuth, and M. E. Berens Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis J. Cell Sci., November 1, 2003; 116(21): 4409 - 4417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-y. Huang, Y. Wu, S. P. Burke, and D. H. Gutmann The 43,000 Growth-associated Protein Functions as a Negative Growth Regulator in Glioma Cancer Res., June 1, 2003; 63(11): 2933 - 2939. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
